Follow-on treatment study for dabrafenib and trametinib
Treatments studied
Part of Cancer, Lungs & breathing, Skin clinical trials.
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking dabrafenib and/or trametinib as part of a completed Novartis or former GSK study.
- That earlier study must have met its main study goals (primary objective).
- Your study doctor believes you would benefit from continuing treatment.
- You were not permanently taken off the study medicines in the original (parent) study.
- You do not have any ongoing, unresolved side effects that caused your dabrafenib/trametinib doses to be paused in the original study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BI 3810944 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
This study checks on the long-term health of adults with melanoma who took part in a previous treatment study. It aims to see how participants are doing over time after receiving the new therapy.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This study tests if giving you targeted therapy pills (encorafenib and binimetinib) only when a blood test shows your cancer is active — instead of continuously — can help keep the melanoma under control with fewer side effects. It is designed for people with advanced melanoma that has a BRAF mutation.
This trial tests TRK-950 in people with advanced (locally advanced or metastatic) solid tumors when standard treatments have stopped working or aren’t available. It may help by trying a new treatment approach when current options are limited.
This study lets people who were already getting encorafenib and binimetinib in an earlier trial keep taking these medicines if they are doing well on them. It provides a way to continue treatment without a gap.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.